Acadia Pharmaceuticals | Pasivo Circulante



Current Liabilities Cambio Fecha
Acadia Pharmaceuticals USD 394.87M 50.92M 2024-12
ALKERMES USD 465.2M 11.5M 2024-12
Alnylam Pharmaceuticals USD 1.19B 34.39M 2024-12
Biogen USD 5.53B 103.8M 2024-12
BioMarin Pharmaceutical USD 606.99M 108.67M 2024-12
Bristol-Myers Squibb USD 23.77B 1.14B 2024-12
Corcept Therapeutics USD 140.77M 14.56M 2024-12
Cytokinetics USD 179.67M 69.86M 2024-12
Eisai JPY 381.62B 54.78B 2024-12
Eli Lilly USD 28.38B 3.7B 2024-12
Incyte USD 1.64B 140.2M 2024-12
J&J USD 50.32B 1.44B 2024-12
Moderna USD 2.21B 5M 2024-12
Neurocrine Biosciences USD 507.7M 78M 2024-12
Pfizer USD 43B 216M 2024-12
Prothena USD 48.5M 2.08M 2024-12
PTC Therapeutics USD 580.98M 29.73M 2024-12
Sarepta Therapeutics USD 731.68M 32.2M 2024-12
Ultragenyx Pharmaceutical USD 344.15M 59.14M 2024-12
Vertex Pharmaceuticals USD 3.56B 408.5M 2024-12



Acadia Pharmaceuticals Pasivo Circulante - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Apr 2025.